谷氨酰胺(Gln)活性肽营养液的研究进展

对G1n小肽在氨基酸营养液中的使用以及G1n小肽的稳定性和代谢机制进行了论述。G1n是一种“条件必需氨基酸”，但Cln的水溶液不稳定，因而在氨基酸输液或氨基酸营养被中，用G1n小肽代替G1n单体使用。G1n小肽含有取代的α—NH2，使Cln小肽的稳定性大大增加。     

无氢类金刚石碳膜的研究进展

介绍了无氢类金刚石碳膜的制备方法 ,它们的机械、光学、电学性能 ,将无氢与含氢的类金刚石碳膜进行了简单比较 ,总结及探讨了它们的应用     

长链烯烃-苯烷基化反应的分子筛催化剂再生性能的研究

通过热重分析和活性稳定性评定考察催化剂的再生性能。研究结果表明,进行氯气吹扫以及苯抽提后进行氮气吹扫两种预处理,导致失活催化剂的起燃点和烧焦反应活化能均有所提高,有利于控制烧焦反应速度。按苯抽提、氮气吹扫、烧焦的顺序,分三个阶段进行催化剂再生,再生催化剂的活性稳定性得到更充分的恢复。     

飞行人员骨密度与内分泌调节关系的探讨

对37名骨密度(BD)低下的飞行员(实验组)和BD正常的48名飞行员、100名地面人员(正常对照组)进行了BD和血清TT_3、TT_4、TSH IRMA、CT、PTH、E_2和T放射免疫测定。结果显示,实验组BD均值明显低于对照组(p<0.01),血清TT_3、TT_4、CT、E_2(女性)和T(男性)均值与对照组比较,大多数年龄存在着显著或非常显著差异(p<0.05或p<0.01)。同时对飞行人员BD与几种内分泌激素关系进行了探讨。     

葡萄糖电解氧化还原工艺研究

采用自制的无膜电解槽，对同时电解氧化还原葡萄糖生成葡萄糖酸和山梨醇的工艺进行了研究。所得到的最佳工艺条件为：葡萄糖浓度０．４ｍｏｌ／Ｌ，ｐＨ值１１，电流密度３Ａ／ｄｍ￣２。在此条件下电解１２ｈ，葡萄糖转化率可达９６．４％，葡萄糖酸产率８８％，山梨醇产率１０％。同时，考察了和Ｚｎ￣（２＋）加入以及ｐＨ值对电流效率的影响。     

Characterization of Dip-Coated Boron Nitride on Silicon Carbide Fibers

Amorphous boron nitride thin coatings (∼0.2 μm) have been formed on Nicalon and C-Nicaion (pre-carbon-coated Nicalon) yarns via dip coating in boric acid solution followed by heating and nitriding in NH₃gas at 1000°C. X-ray photoelectron spectroscopy (XPS) and Auger electron spec-troscopy (AES) studies have shown the formation of boron nitride. The coating was boron rich and contains oxygen. The N/B and O/B ratios range from 0.6 to 0.8 and from 0.1 to 0.25, respectively. Tensile strength measurements revealed that the BN-coated C-Nicalon yarn maintained ∼85% of its original strength while BN-coated Nicalon lost ∼85% of its original strength. Auger depth profiles showed that there was a consumption of carbon during the heating and nitridation process for both BN-coated Nicalon and C-Nicalon fibers. However, the depletion of carbon in BN-coated Nicalon fibers was much more severe than that in BN-coated C-Nicalon fibers.     

Post-traumatic stress disorder and smoking: a systematic review.

We conducted a systematic review of what is known about the relationship between post-traumatic stress disorder (PTSD) and smoking to guide research on underlying mechanisms and to facilitate the development of evidence-based tobacco treatments for this population of smokers. We searched Medline, PsychINFO, and the Cochrane Central Register of Controlled Trials and identified 45 studies for review that presented primary data on PTSD and smoking. Smoking rates were high among clinical samples with PTSD (40%-86%) as well as nonclinical populations with PTSD (34%-61%). Most studies showed a positive relationship between PTSD and smoking and nicotine dependence, with odds ratios ranging between 2.04 and 4.52. Findings also suggest that PTSD, rather than trauma exposure itself, is more influential for increasing risk of smoking. A small but growing literature has examined psychological factors related to smoking initiation and maintenance and the overlapping neurobiology of PTSD and nicotine dependence. Observational studies indicate that smokers with PTSD have lower quit rates than do smokers without PTSD. Yet a few tobacco cessation treatment trials in smokers with PTSD have achieved quit rates comparable with controlled trials of smokers without mental disorders. In conclusion, the evidence points to a causal relationship between PTSD and smoking that may be bidirectional. Specific PTSD symptoms may contribute to smoking and disrupt cessation attempts. Intervention studies that test behavioral and pharmacological interventions designed specifically for use in patients with PTSD are needed to reduce morbidity and mortality in this population.